Cargando…

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intrace...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hong Yun, Das, Jeeban, Prendergast, Conor, De Jong, Dorine, Braumuller, Brian, Paily, Jacienta, Huang, Sophia, Liou, Connie, Giarratana, Anna, Hosseini, Mahdie, Yeh, Randy, Capaccione, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/
https://www.ncbi.nlm.nih.gov/pubmed/37998743
http://dx.doi.org/10.3390/cimb45110566
_version_ 1785139902691672064
author Ma, Hong Yun
Das, Jeeban
Prendergast, Conor
De Jong, Dorine
Braumuller, Brian
Paily, Jacienta
Huang, Sophia
Liou, Connie
Giarratana, Anna
Hosseini, Mahdie
Yeh, Randy
Capaccione, Kathleen M.
author_facet Ma, Hong Yun
Das, Jeeban
Prendergast, Conor
De Jong, Dorine
Braumuller, Brian
Paily, Jacienta
Huang, Sophia
Liou, Connie
Giarratana, Anna
Hosseini, Mahdie
Yeh, Randy
Capaccione, Kathleen M.
author_sort Ma, Hong Yun
collection PubMed
description Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.
format Online
Article
Text
id pubmed-10670348
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106703482023-11-12 Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer Ma, Hong Yun Das, Jeeban Prendergast, Conor De Jong, Dorine Braumuller, Brian Paily, Jacienta Huang, Sophia Liou, Connie Giarratana, Anna Hosseini, Mahdie Yeh, Randy Capaccione, Kathleen M. Curr Issues Mol Biol Review Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene. MDPI 2023-11-12 /pmc/articles/PMC10670348/ /pubmed/37998743 http://dx.doi.org/10.3390/cimb45110566 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ma, Hong Yun
Das, Jeeban
Prendergast, Conor
De Jong, Dorine
Braumuller, Brian
Paily, Jacienta
Huang, Sophia
Liou, Connie
Giarratana, Anna
Hosseini, Mahdie
Yeh, Randy
Capaccione, Kathleen M.
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title_full Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title_fullStr Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title_full_unstemmed Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title_short Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
title_sort advances in car t cell therapy for non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/
https://www.ncbi.nlm.nih.gov/pubmed/37998743
http://dx.doi.org/10.3390/cimb45110566
work_keys_str_mv AT mahongyun advancesincartcelltherapyfornonsmallcelllungcancer
AT dasjeeban advancesincartcelltherapyfornonsmallcelllungcancer
AT prendergastconor advancesincartcelltherapyfornonsmallcelllungcancer
AT dejongdorine advancesincartcelltherapyfornonsmallcelllungcancer
AT braumullerbrian advancesincartcelltherapyfornonsmallcelllungcancer
AT pailyjacienta advancesincartcelltherapyfornonsmallcelllungcancer
AT huangsophia advancesincartcelltherapyfornonsmallcelllungcancer
AT liouconnie advancesincartcelltherapyfornonsmallcelllungcancer
AT giarratanaanna advancesincartcelltherapyfornonsmallcelllungcancer
AT hosseinimahdie advancesincartcelltherapyfornonsmallcelllungcancer
AT yehrandy advancesincartcelltherapyfornonsmallcelllungcancer
AT capaccionekathleenm advancesincartcelltherapyfornonsmallcelllungcancer